Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: Bernd Kieseier Clear advanced filters

  • A number of established therapies are available for multiple sclerosis (MS), but the advent of numerous novel therapies has meant that treatment decisions for MS are becoming increasingly complex. In this Review, Kieseier and Stüve discuss the challenges that both neurologists and patients face in terms of treatment decision-making, and highlight the risks, benefits and treatment paradigms associated with MS therapy.

    • Bernd C. Kieseier
    • Olaf Stüve
    Reviews
    Nature Reviews Neurology
    Volume: 7, P: 255-262

  • In recent years, considerable progress has been made towards understanding the mechanisms that underlie autoimmune inflammatory diseases of the PNS, such as Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy. As Meyer zu Hörste et al. discuss in this Review, many promising therapeutic approaches for these conditions have been established in animal models, but attempts to transfer this knowledge to the clinic have met with limited success to date.

    • Gerd Meyer zu Hörste
    • Hans-Peter Hartung
    • Bernd C Kieseier
    Reviews
    Nature Clinical Practice Neurology
    Volume: 3, P: 198-211

  • Using large cohorts from published clinical trials involving more than 8,000 patients with multiple sclerosis, a probabilistic machine learning model reconstructs the transition probabilities from data-derived diseases statuses, showing patterns that suggest how progression to severe stages occur and potential inversion of the process.

    • Habib Ganjgahi
    • Dieter A. Häring
    • Chris C. Holmes
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 3414-3424

  • Only moderately effective therapies are currently available for the treatment of multiple sclerosis (MS). New treatments for MS that have neuroprotective properties as well as anti-inflammatory effects are needed. Fingolimod could be one such potential treatment. In this article, Aktas et al. examine the underlying biological actions of this prospective new therapy, review the data from phase II and phase III oral fingolimod clinical trials and provide an update on the emerging field of sphingosine-1-phosphate receptor-mediated therapies for MS.

    • Orhan Aktas
    • Patrick Küry
    • Hans-Peter Hartung
    Reviews
    Nature Reviews Neurology
    Volume: 6, P: 373-382

  • Combination therapy is a rational strategy to optimize therapeutic benefits and minimize risks associated with treatment of patients with multiple sclerosis (MS). A recent study reporting negative results of combination therapy in MS should not discourage investigators from future attempts to identify optimal combinations for the treatment of this disease.

    • Bernd C. Kieseier
    • Olaf Stüve
    News & Views
    Nature Reviews Neurology
    Volume: 7, P: 659-660

  • Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

    • Heinz Wiendl
    • Bernd Kieseier
    News & Views
    Nature Reviews Neurology
    Volume: 9, P: 125-126

  • There is increasing evidence to indicate that the immune system has a central role in the pathogenesis of multiple sclerosis. In this review, Hemmer et al. present findings from animal and human studies that have provided important insights into the immunology of multiple sclerosis, and discuss how this knowledge is guiding the development of new therapeutic strategies.

    • Bernhard Hemmer
    • Stefan Nessler
    • Hans-Peter Hartung
    Reviews
    Nature Clinical Practice Neurology
    Volume: 2, P: 201-211

  • This Primer discusses the epidemiology, mechanisms, differential diagnosis and management of the immune-mediated neuropathies — a large group of disorders that includes Guillain–Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy, among other disorders.

    • Bernd C. Kieseier
    • Emily K. Mathey
    • Hans-Peter Hartung
    Reviews
    Nature Reviews Disease Primers
    Volume: 4, P: 1-23

  • Although the most common neuropathy associated with diabetes mellitus is distal symmetric polyneuropathy, inflammatory neuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP) can also occur, and might be amenable to treatment. In this Review, Rajabally et al. consider the features of CIDP in diabetes, how this condition can be differentiated from other neuropathies, and management options for CIDP and other inflammatory neuropathies in diabetes.

    • Yusuf A. Rajabally
    • Mark Stettner
    • Rayaz A. Malik
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 599-611